Browsing tag:

Ibrutinib


The early EU approval for Ibrutinib was granted by the European Commission (EC), for Ibrutinib to be sold in the 28 European Union (EU) member states. Ibrutinib is a first-in-class, oral, once-daily, non-chemotherapy treatment option, and will be used to treat adult patients with relapsed or refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).[…]

Read More

Patients suffering from chronic lymphocytic leukemia {CLL} or small lymphocytic lymphoma {SLL} can breathe easier with the latest findings regarding Ibrutinib. Study results revealed at the beginning of June 2014 showed that the powerful anti-cancer drug Ibrutinib elicited a significant improvement for patients with either chronic lymphocytic leukemia or small lymphocytic lymphoma in both overall[…]

Read More

Exciting new was recently revealed from Pharmacyclics, when it was announced that the New Drug Application for Ibrutinib was placed on a priority basis by the FDA. This NDA for Ibrutinib is applicable in two different oncology indications. The first indication for Ibrutinib is for patients with mantle cell lymphoma (MCL) who have received prior[…]

Read More

The advent of the FDA Safety and Innovation Act of 2012 has led to an onslaught of new cancer treatments waiting to be approved. Now that the FDA can legally create a new status, known as a “breakthrough” designation, patients with life-threatening diseases such as cancer can obtain their medications faster and more efficiently. However,[…]

Read More

Ibrutinib was a shining star in the pharmaceutical headlines on June 20, 2013, with the news that this experimental drug used to treat chronic lymphocytic leukemia may be the next breakthrough cancer treatment. As a medication Ibrutinib is different from the usual chemotherapy treatments in that it pointedly targets specific processes, and prevents tumor proliferation.[…]

Read More